Evidence map›Paper›PMID 27941393›Full record

Trial reportAIDS (London, England)2017

Use of rosuvastatin in HIV-associated chronic obstructive pulmonary disease.

Alison Morris, Meghan Fitzpatrick, Marnie Bertolet, Shulin Qin, Lawrence Kingsley, Nicolas Leo, Cathy Kessinger, Heather Michael, Deborah Mcmahon, Renee Weinman and 5 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in AIDS (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01881971 (Multicenter, Prospective Adaptive Response Placebo-controlled Double-blind Study Comparing Effects of Rosuvastatin Versus Placebo), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01881971 early_phase1completednot on this map

Multicenter, Prospective Adaptive Response Placebo-controlled Double-blind Study Comparing Effects of Rosuvastatin Versus Placebo

TypeinterventionalSponsorAlison MorrisRan2013 to 2016Enrolled23ConditionsHIV SeropositivityArmsPlacebo, Rouvastatin calcium
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. COPD in People with HIV: Epidemiology, Pathogenesis, Management, and Prevention Strategies.International journal of chronic obstructive pulmonary disease · 2023
    Review
  5. Review
  6. Chronic obstructive pulmonary disease in HIV.Expert review of respiratory medicine · 2021
    Review
  7. Review
  8. Review
  9. Lung Function, Coronary Artery Disease, and Mortality in HIV.Annals of the American Thoracic Society · 2019
    Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Alison MorrisaDepartment of Medicine bEpidemiology Data Coordinating Center, University of Pittsburgh School of Medicine cGraduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania dDepartment of Medicine, University of California San Francisco, San Francisco, California eDepartment of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania fDepartment of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Meghan Fitzpatrick
Marnie Bertolet
Shulin Qin
Lawrence Kingsley
Nicolas Leo
Cathy Kessinger
Heather Michael
Deborah Mcmahon
Renee Weinman
Stephen Stone
Joseph K Leader
Eric Kleerup
Laurence Huang
Stephen R Wisniewski
University of Pittsburgh · USUniversity of California, San Francisco · USApple (Israel) · IL

Funding

University of Pittsburgh Multicenter AIDS Cohort Study (MACS)U01AI035041 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MARTINSON, JEREMY JAMES, RINALDO, CHARLES R · 1993 to 2018
$71.4M
Center for the Analysis & Management of the Multicenter AIDS Cohort StudyUM1AI035043 · NIAID · JOHNS HOPKINS UNIVERSITY · PI D'SOUZA, GYPSYAMBER, JACOBSON, LISA P · 2012 to 2018
$20.7M
Institute for Clinical and Translational ResearchUL1TR000424 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2012 to 2012
$6.0M
Prevalence & Pathogenesis of Pulmonary Disease in a Large Multicenter HIV CohortR01HL090339 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MORRIS, ALISON · 2007 to 2011
$4.0M
Pneumocystis in Pathogenesis of HIV-associated EmphysemaR01HL083461 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MORRIS, ALISON · 2005 to 2009
$2.2M
Patient-Oriented Research and Mentoring in PneumocystisK24HL087713 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HUANG, LAURENCE · 2006 to 2018
$1.8M
Statins for Pulmonary and Cardiac Complications of Chronic HIV (The SPARC Trial)R34HL117344 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KINGSLEY, LAWRENCE A., MORRIS, ALISON · 2012 to 2013
$1.2M
Mentoring and Patient-Oriented Research in HIV Obstructive Lung DiseaseK24HL123342 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MORRIS, ALISON · 2014 to 2018
$571k
NCATS NIH HHS UL1 TR000424NHLBI NIH HHS K24 HL087713NHLBI NIH HHS K24 HL123342NHLBI NIH HHS R01 HL083461NHLBI NIH HHS R01 HL090339NHLBI NIH HHS R34 HL117344NIAID NIH HHS U01 AI035041NIAID NIH HHS UM1 AI035043
6 · The paper itself

Abstract

objectivesChronic obstructive pulmonary disease (COPD) is more prevalent in HIV-infected individuals and is associated with persistent inflammation. Therapies unique to HIV are lacking. We performed a pilot study of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin to determine effects on lung function.

designRandomized, placebo-controlled, triple-blinded trial.

methodsHIV-infected individuals with abnormal lung function were recruited from an ongoing lung function study. Participants were randomized to 24 weeks of placebo (n = 11) or rosuvastatin (n = 11) using an adaptive randomization based on change in peripheral C-reactive protein levels at 30 days of treatment. Forced expiratory volume in 1 s (FEV1) and diffusing capacity for carbon monoxide (DLco)%-predicted were compared to baseline at 24 weeks in the two groups using a Wilcoxon rank-sum test. The %-predicted change at 24 weeks in pulmonary function variables was compared between groups using simulated randomization tests.

resultsThe placebo group experienced a significant decline in FEV1%-predicted (P = 0.027), and no change in DLco%-predicted over 24 weeks. In contrast, FEV1%-predicted remained stable in the rosuvastatin group, and DLco%-predicted increased significantly (P = 0.027). There was no significant difference in absolute change in either measure between placebo and rosuvastatin groups.

conclusionIn a pilot study, the use of rosuvastatin for 24 weeks appeared to slow worsening of airflow obstruction and to improve DLco in HIV-infected individuals with abnormal lung function, although comparison of absolute changes between the groups did not reach significance. This study is the first to test a therapy for COPD in an HIV-infected population, and large-scale clinical trials are needed.

Indexed as

AdolescentAdultAgedAged, 80 and overAnticholesteremic AgentsFemaleHIV InfectionsHumansMaleMiddle AgedPilot ProjectsPlacebosProspective StudiesPulmonary Disease, Chronic ObstructiveRespiratory Function TestsRosuvastatin CalciumAnticholesteremic AgentsPlacebosRosuvastatin Calcium

Identifiers

PMID27941393
PMCPMC5263188
OpenAlexW2560811774

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.